Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

The tool predicts which of two standard front-line chemotherapy options a patient with advanced pancreatic cancer is likely to benefit from.

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

NEW YORK – A bill introduced in Idaho this month seeking to delicense genetic counselors will not move ahead this legislative session. Earlier this month, Jeff Ehlers, a Republican representing the ...

In a Phase III trial, 28 percent of newly diagnosed patients with H3 K27M-mutant diffuse glioma responded to treatment with dordaviprone.

The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.

The firm is seeking accelerated approval for UX111 using reductions in levels of heparan sulfate in cerebrospinal fluid as a surrogate endpoint.

The firm will offer up to 12,030,218 common shares for Keystone Capital Partners to sell and is expecting to net around $2.1 million in gross proceeds.